The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
I am an Opthalmologist specialising in the treatment of glaucoma and genetic eye diseases. I am trained in Molecular Genetics and researching the genetic causes of eye diseases, and how understanding the basis of disease will lead to improved outcomes.
An Innovative Health Services & Translational Eye Research Program For Australians Living With Eye Diseases
Funder
National Health and Medical Research Council
Funding Amount
$256,801.00
Summary
My research is focused on the prevention; treatment; and improvement in the quality of life of people with eye diseases, in particular those with diabetic retinopathy (DR), the most common complication of diabetes and a blinding eye condition. My work focuses on three main areas: (a) determining the effectiveness of interventions to prevent and treat DR; (b) evaluating new therapies and biomarkers for DR; (c) evaluating patient-centred, clinical, and economic effectiveness of new treatments for ....My research is focused on the prevention; treatment; and improvement in the quality of life of people with eye diseases, in particular those with diabetic retinopathy (DR), the most common complication of diabetes and a blinding eye condition. My work focuses on three main areas: (a) determining the effectiveness of interventions to prevent and treat DR; (b) evaluating new therapies and biomarkers for DR; (c) evaluating patient-centred, clinical, and economic effectiveness of new treatments for other eye diseases.Read moreRead less